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Available online 29 June 2019Background: The complement system is a central component of the innate immune system. Constitutive
biosynthesis of complement proteins is essential for homeostasis. Dysregulation as a consequence of genetic or
environmental cues can lead to inﬂammatory syndromes or increased susceptibility to infection. However,
very little is known about steady state levels in children or its kinetics during infection.
Methods: With a newly developed multiplex mass spectrometry-based method we analyzed the levels of 32
complement proteins in healthy individuals and in a group of pediatric patients infected with bacterial or viral
pathogens.
Findings: In plasma from young infants we found reduced levels of C4BP, ﬁcolin-3, factor B, classical pathway
components C1QA, C1QB, C1QC, C1R, and terminal pathway components C5, C8, C9, as compared to healthy
adults; whereas the majority of complement regulating (inhibitory) proteins reach adult levels at very young
age. Both viral and bacterial infections in children generally lead to a slight overall increase in complement levels,
with some exceptions. The kinetics of complement levels during invasive bacterial infections only showedminor
changes, except for a signiﬁcant increase and decrease of CRP and clusterin, respectively.
Interpretation: The combination of lower levels of activating and higher levels of regulating complement proteins,
would potentially raise the threshold of activation,whichmight lead to suppressed complement activation in the
ﬁrst phase of life. There is hardly any measurable complement consumption during bacterial or viral infection.
Altogether, expression of the complement proteins appears surprisingly stable, which suggests that the system
is continuously replenished.
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The complement system is one of the oldest immune defensemech-
anisms and is highly conserved in all vertebrates [1]. This network ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
Knowledge of the complement system in pediatric infectious dis-
eases is still limited; presumably due to the lack of methods to
study multiple complement proteins simultaneously. The comple-
ment system has different strategies to recognize specific patho-
gens, which could imply putative pathogen-specific depletion of
the affected complement proteins and pathways. For several com-
plement proteins conflicting results are reported on possible
gender-dependent effects and lower steady state levels during
childhood.
Added value of this study
In this studywe demonstrate the application of a newly developed
method to measure 32 complement proteins in multiplex using
sensitive and specific targeted mass spectrometry. We compared
healthy individuals ranging from 0 to 55 years of age and observed
lower complement levels in infants for a subset of the measured
complement proteins. However, we did not observe a gender ef-
fect for either the healthy or infected patient group. There was
no distinct complement level signature for specific infections.
We show that the complement levels remain stable during infec-
tion, with the exception of CRP and clusterin.
Implications of all the available evidence
The levels of several classical pathway proteins are lower in the
first year of life; whereas most inhibiting factors are already at
adult levels. This might indicate that complement activation is
more suppressed in newborns. During infections the levels of com-
plement proteins remain stable, except for CRP and clusterin,
which indicates that the complement proteins are continuously
replenished to maintain an immune response.
304 E. Willems et al. / EBioMedicine 45 (2019) 303–313proteins, forming a sophisticated biological reaction system, plays an
important role in the orchestration of both the innate and adaptive im-
mune defense and is involved in the repair or clearance of damaged
cells [2–4]. Not surprisingly, unpremeditated activation of the comple-
ment system results in inﬂammatory syndromes, autoimmunity
disorders, neuro-degenerative diseases, biomaterial rejection and
cancer development [5–7].
Most of the approximately 50 complement proteins are constitu-
tively expressed and mainly synthesized in the liver. The nearly 40 sol-
uble constituents are highly abundant in blood as circulating inactive
precursors. The complement system is activated via three main path-
ways: the classical, lectin and alternative pathway [7]. Activation of
each of these proteolytic cascades leads to cleavage of complement
components C3 and C5 which are key proteins in all activation path-
ways (Fig. 1). Tissue factors and coagulation proteins, such as kallikrein,
thrombin, factors XIa, Xa, IXa, and plasmin, can also directly cleave C3
and C5. This extrinsic complement pathway clearly indicates intercon-
nections between the complement and the coagulation system [8,9].
The speciﬁc cleavage products from the complement cascade act in
multiple ways. They can induce inﬂammatory responses (C3a, C5a), en-
hance phagocytosis (C3b), and create pores (C5b-C9) in the pathogen's
membrane leading to lysis [2]. Themain function ofmore than one third
of the proteins in this extensive system is inhibiting unpremeditated or
excessive activation, which emphasizes the importance of strict regula-
tion of this intricate ‘trigger-ready’ system.
Interestingly, the complement system uses several different ap-
proaches to recognize and inactivate speciﬁc types of bacteria andviruses, as described by Stoermer et al. [10]. At the same time, various
pathogens have developed their own unique strategies to evade the
complement systemas reviewed by Bennett et al. [11]. The evolutionary
determined interplay between host and pathogen has resulted in this
reﬁned complex protein system, produced for continuous immune sur-
veillance and homeostasis. This might have led to the pathogen-speciﬁc
activation pathways, reﬂected by altered expression levels of pathway-
speciﬁc components during infection. This would provide unique possi-
bilities to diagnose pathogen-speciﬁc infections based on the comple-
ment protein proﬁle. However, little is known about how infection
inﬂuences the plasma complement protein levels.
Deﬁciencies in the complement system leading to reduced concen-
trations and/or less activity increase the vulnerability for infection, es-
pecially with invasive bacterial species like Neisseria meningitidis or
Streptococcus pneumoniae [5,12,13]. Particularly newborns and young
children are at high risk as their immune system is still under develop-
ment [14–16]. Yet, knowledge of the complement system in children
and its role in pediatric disease is still limited. Also little is known with
respect to the production and basal levels of the complement proteins.
Reference levels of all 40 circulating complement proteins are
unreported and many diagnostic laboratories use their own databases
to determine deviating concentrations. We therefore designed and de-
veloped a reproducible and speciﬁc method to measure complement
proteins in multiplex, enabling the measurement of large numbers of
plasma samples obtained from healthy individuals from different age
groups, as described in this study.
Studies of complement levels (mainly C1 to C9, factor B, D, H, I and
properdin) in newborns conducted between 1970 and 1995 described
that most complement levels are at 50–70% of the adult values, rising
to adult concentrations within 6 months [16–20]. Other studies in
young infants have reported complement C3, C7 and factor D at adult
levels or even higher [19,20]. In the last two decades, few studies have
been performed to determine normal complement concentrations in
children using standardized methods. Only recently studies have been
conducted in which no signiﬁcant age-dependent differences were
found for C3, factor H, factor I and FHR-1 to FHR-5 [21,22].
Furthermore, publicly available basal complement levels in
adults, apart from C3 and C4 [23], mostly date back to the 1970's [24].
However, a recent publication describes complement levels in adults
(20–69 years) for 19 complement proteins measured by independent
ELISAs, but focuses more on pathway and gender differences [25]. In
conclusion, conﬂicting results are reported on several complement pro-
tein levels during childhood, possibly due to the use of less accurate
techniques such as radial immunodiffusion and immunoelectrophoresis
in older studies. Recent comprehensive studies on complement protein
levels are based on adult levels, so it remains unknown if there are dif-
ferences in complement levels in various age groups and if these levels
change during infection.
Only a limited number of complement proteins are currently used in
research and diagnosis, determined by singleplex ELISA or nephelomet-
ric tests [26]. Recently, liquid chromatography (LC), mostly combined
withmass spectrometry (MS) detection, is increasingly used for protein
quantitation in research and diagnostics [27–30]. Although mass spec-
trometry is not an immediate alternative for the ease-of-use and high-
throughput immunoassays, the requirement of a few microliters of
sample and its high speciﬁcity and reproducibility make LC-MS an at-
tractive option [31]. Furthermore, LC-MS is a highly suitable method
for multiplexed protein analysis, providing the possibility to capture a
proﬁle of proteins. This is highly relevant in the case of multi-factorial
complement-mediated diseases, as a complete overview of all the com-
plement proteinsmeasured simultaneouslywill help to unravel mecha-
nisms of complement-mediated diseases and may facilitate diagnosis
and monitoring of treatment.
Our aim was to develop a multiplex reaction monitoring (MRM)
assay targeting the 40 soluble plasma complement proteins to obtain
a detailed protein abundance proﬁle of the complement system. By
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and relatively quantify 64 targeted peptides, representing 32 comple-
ment proteins. Using this new assay, we compared the basal levels of
these complement peptides in both healthy adults and healthy children.
We also used this assay to perform a pilot study of 75 pediatric patients
diagnosed with either a bacterial or viral infection to study differences
in the complement system. Furthermore, we investigated patients in-
fectedwith invasive bacterial pathogens atmultiple timepoints tomon-
itor complement kinetics during infection in more detail. In overall
perspective, the complement system appears surprisingly resilient,
which is probably due to high protein turnover, sustaining homeostasis
in order to maintain its biological function. The high speciﬁcity and re-
producibility of this multiplex complement assay has the potential to
be applied for the diagnosis of complement-mediated diseases.
2. Materials and methods
2.1. Study approval for patients and healthy donors
For this study a group of 75 children (0–18 years) diagnosed with
either a deﬁnite bacterial infection (n=44), or a deﬁnite viral infectionCRP
Classical pathway
C1q-a C1q-bC1q-c
C1r C1s
Lecn pathway
MBL2
ﬁcolin1 ﬁcolin2
ﬁcolin3collecn11
MASP-1 MASP-2 MASP-3
C2 C4
C2bC4a
+
2 2
C4b2a (C3 convertase)
Mannoses, fucoses 
sugars on cell surface
A
+
MBL-MASP
(bound to cell suface)
C3a C3
factor D
(C3 c
C3b
C4b2a3b
(C5 convertase)
C5
C5a C6 C7
C5b
C4a-desR
Terminal pathway
Inﬂammaon
C1 complex
s(C1qr )
C1-inh
CPN
CPN
factor H
C4BP
CR1
MCP
DAF
Ag-Ab complex, apotoc cells, 
β-amyloid and CRP and N-acetylated
C3a-desR
C5a-desR
MASP = MBL-Associated Serine Proteases  
TCC = Terminal Complement Complex  
C4BP = C4 Binding Protein
inhibion
cleavage
conversion
acvaon
complex
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admission and at recovery (ranging between 3 and 49 days). All sam-
ples were part of the EUCLIDS [32,33], IRIS [34] and VENTURIUS [35]
studies, which were approved by the Medical Ethical Committees of
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The selectionwas based on an equal distribution of the type of causative
pathogen, gender and age.
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of the Human-related Research Committee Arnhem-Nijmegen. Exclu-
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this study are summarized in supplementary table S1.
2.2. Sample collection
Patient plasma samples were collected and frozen as described pre-
viously (EUCLIDS [32,33], IRIS [34] and VENTURIUS [35]). The selected
samples were shipped on dry ice and stored at −80 °C upon arrival.
Plasma samples from the pediatric healthy subjects [21] and healthy
adult volunteers were placed on ice immediately after collection and
were processed within 1 h (10 min, 2500g, 4 °C). Aliquots were stored
at−80 °C.
2.3. MRM method development
Out of N10.000 potential candidate peptides, representing 40 com-
plement proteins, we selected 120 candidate target peptides in silico,
with each 10 transitions, based on both technical and biological proper-
ties. We combined information from several sources (a.o. PeptideAtlas
[36], Uniprot [37], dbSNP [38] and built-in restriction options of Skyline
[39]), taking into account features including: uniqueness, length of the
peptide, susceptibility to possible post-translational or chemicalmodiﬁ-
cations, SNPs, isoforms, incomplete proteolysis, and hydrophobicity.
After mass spectrometric analysis of pooled digested plasma (5 con-
trols and 5 patients) at least 2 peptides were selected for each protein
subunit (n = 86), using the most predominant charge state and the 5
transitions with highest intensity. C-terminally 13C15N stable isotope la-
beled “heavy”peptides (Thermo, JPT)were used to optimize instrument
settings for each peptide speciﬁc (cone voltage and collision energy)
and to spike the samples for identiﬁcation and relative quantiﬁcation.
Based on the results, a scheduled MRM method was created using re-
tention time windows of 2 min each and was designed in such way
that both endogenous and stable isotope labeled peptides could be an-
alyzed with 3 transitions per precursor and at least 8 data points per
chromatographic peak using dwell times of 30–50 ms.
2.4. Sample preparation
Sampleswere prepared in a randomized order. Total protein content
was determined using the 2D Quant kit (GE Healthcare). Proteins were
reduced with dithiothreitol (DTT) (1 μl 10 mM DTT/50 μg protein) for
30 min at RT. Reduced cysteines were alkylated through incubation
with 2-chloroacetamide (CAA) (1 μl 50 mM CAA/50 μg protein) in the
dark for 30 min at RT. Next, proteins were subjected to LysC digestion
(1 μg LysC/50 μg protein) by incubating the sample at RT for 3 h. Then,
samples were diluted with 3 volumes of 50 mM ammonium bicarbon-
ate and trypsinwas added (1 μg trypsin /50 μg protein) for overnight di-
gestion at 37 °C. Samples were spiked with a mix of C-terminally
13C15N-stable isotope (Arg-10 or Lys-8) labeled peptide standards
(Thermo, JPT) of the targeted complement component peptides. Subse-
quently, sampleswere desalted and concentrated using BondElut OMIX
tips (Agilent). The eluates were evaporated until a fewmicroliters using
a vacuum concentrator (Thermo) at 30 °C for 20 min and reconstituted
in 0·1% formic acid. Samples were stored at−80 °C until analysis. All
peptides containing a methionine were oxidized with 0·3% peroxide
prior to analysis to obtain 100% methionine oxidation [40] and were
measured separately.
2.5. Mass spectrometric analysis
Samples were analyzed in randomized order using the Waters
Acquity MClass UPLC Xevo TQ-S, equipped with an ionKey/MS sytem
using a Waters peptide BEH C18, 130 Å, 1·7 μm, 150 μmx100mm iKey
for chromatographic separation. The systemwas conﬁgured in direct in-
jectionmode. Peptideswere eluted from the column using a 20min lin-
ear gradient of 3 to 35% acetonitrile in 0·1% formic acid at aﬂow rate of 2μl/min. The following MS conditions were used: ESI positive ionization
mode, capillary voltage 4.0 keV, source temperature 120 °C, cone gas
ﬂow 30 l/h, nebulizer 7·0 bar, collision gas ﬂow (0·15ml/min). Optimal
precursors and transitions and their corresponding cone voltage and
collision energy (CE) voltageswere set according to preceded optimiza-
tion experiments.
2.6. Data processing and statistical analysis
Raw data were analyzed using Skyline software v4.2.0.18305
(MacCoss Lab, University ofWashington, USA [39]). Typical settings ap-
plied included default peak integration, no peak smoothing, SSRCalc
window of 10 arbitrary units, Q1 mass window of 0.7 Th, Q3 window
of 1·0 Th, considered isotopes up to 3 amu. The dataset was manually
inspected to ensure correct peak detection and integration.
The respective peak areas of both transitions were summed for the
endogenous (L1 and L2) and spiked heavy labeled standard (H1 and
H2), and the (L1 + L2)/(H1 + H2) * 100 ratio was determined for each
peptide using an in-house developed MATLAB routine (version 2014b,
The MathWorks, USA).
For each peptide the relative fragment ion intensities of the endoge-
nous (light, L) and spiked heavy labeled standard (heavy, H)were com-
pared using Pearson's correlation. Transitions with a correlation of b0.6
(mainly due to high background signals) were considered as outliers
and were excluded from the method. The intra-assay (injections on
same day), inter-assay (injections on different days) and inter-
operator (sample preparation by three different technicians) variability
were assessed for each peptide by means of the coefﬁcient of variation
(CV%) for ﬁve repeated measurements of one pooled digested plasma
sample (5 controls and 5 patients). The stability of the sample in the
auto-sampler was determined for each peptide by the CV% of 13 injec-
tions with intervals of 4 h (total 52 h) of a pooled digested plasma. For
all four tested speciﬁcations a cut-off CV of b20%was used for selection.
The linear regression coefﬁcient of determination (R2) was assessed for
each peptide using a dilution series of a mix of all heavy labeled stan-
dards (0·5; 1; 5, 10; 50; 100; 250; 500; 750; 1000 fmol crude standard,
synthesized by Thermo and JPT) spiked into pooled digested plasma, in
duplicate.
The following statistical tests were performed and created using
standard packages in R (v3.5.2): Pearson's correlation, t-test withmulti-
ple testing correction, hierarchical clustering (1 - correlation as distance
metric), random forest analysis (all 64 features, 500 iterations) and
Principle Component Analysis (PCA). ANalysis Of VAriance (ANOVA)
with Bonferroni's correction for multiple testing was performed using
Graphpad 5.03.
2.7. Data sharing
The Skyline raw datasets can be found online in the Panorama public
repository: https://panoramaweb.org/ikHShd.url
ProteomeXchange ID: PXD014264. All raw and processed data can
be found in a Mendeley Data repository, DOI: 10.17632/bpsr9cdd27.2
3. Results
3.1. Patient and healthy control characteristics
For this study 43 controls and 75 patients were selected from ﬁve
European medical centers, situated in the Netherlands, UK and Spain.
The pediatric patients had either a bacterial or viral infection. The fol-
lowing pathogens were detected in these patients: Streptococcus
pyogenes, Neisseria meningitidis serogroup B, Streptococcus pneumoniae,
Staphylococcus aureus, adenovirus, enterovirus, rhinovirus, or respira-
tory syncytial virus. Gender, age and type of infection were equally dis-
tributed over all groups (Fig. S1). The mean age for the adult controls
307E. Willems et al. / EBioMedicine 45 (2019) 303–313was 36 years, for the young controls and patients 3 years of age. Addi-
tional characteristics for patients and controls are shown in Table S2.
3.2. MRM assay design and validation
During development of the MRM assay, for each peptide target the
peak area, background interference, correlation between fragmentation
patterns, linearity, reproducibility, and robustness were assessed for
both the endogenous and internal standard signals for all transitions.
Based on these characteristics the two out of three best performing
transitions were selected for a total of 86 peptides (Fig. 2). The average
intra-assay variation (reproducibility), inter-assay variation (robust-
ness) and inter-operator (n=3)variationweredetermined by calculat-
ing the coefﬁcient of variation from 5 repeated measurements for each
peptide. In total 22 peptides (26%) were excluded from the dataset be-
cause of poor linearity and/or reproducibility of all its tested transitions
(n=3), no detectable signal for the endogenous peptide (n=13), poor
peak integration (partially outside scheduled detection window or split
peaks) (n=3) and one technical control. This resulted in selection of 64
distinct peptides for 32 different proteins to be measured in multiplex
(Figs. 1, 2 and Table S3). For the ease of reading all peptide sequences
in this study are abbreviated to the ﬁrst three amino acids within
brackets, as listed in Table S3.
3.3. Comparison to the current clinical standard
The MRM peptide levels of CRP (peptide ESD) were compared to
clinical CRP protein values of the same patients, determined at the
time of blood collection, measured with the highly standardized
Roche/Hitachi cobas c system. Six patients were excluded from this
analysis as no clinical CRP values were determined at the time of
blood collection. We observed a strong correlation between the clinical
CRP values and the levels of our LC-MS/MS analysis (Pearson's r of
0·798) (Fig. 3). This indicates that, at least for CRP, the results
from the MRM assay are comparable to clinical state-of-the-art
measurements.
3.4. Complement levels in healthy individuals: age associated effect
To establish basal complement levels in healthy subjects from differ-
ent age groups, we used the multiplex MRM assay to study all 64 pep-
tides in plasma samples from healthy donors from 0 to 55 years old.5 10 15
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Fig. 2.Overview of all peptide targets in the multiplex MRM Complement assay. (a) Combined
endogenous peptide DVWGIEGPIDAAFTR (protein vitronectin),m/z 823·9123 (2+), fragments
standard DVWGIEGPIDAAFTR, m/z 828.9164 (2+), fragments y13, y10, y9, y8, b6. The peptide
as: signal intensity, low interfering background signal, linearity and reproducibility.Although the assay often includes multiple peptides originating from
-different parts of- the same protein, we chose to analyze all MRM re-
sults at the peptide level instead of averaging all peptide results for
one protein. Not all peptides originating from the same protein will
give identical results. This is intrinsic to bottom-up proteomics due to
difference in peptide stability, ionization efﬁciency and existence of
multiple proteoforms [41–43]. Especially complement proteins have
multiple proteoforms due to the proteolytic cleavages in the activation
mechanism of the complement system.
When we compared the peptide levels between healthy adults (age
23–55) and healthy children (0–5) we found a high correlation,
reﬂected by a Pearson's r of 0·992 (Fig. 4a). Only when we compared
the adult group to the healthy infants (b1 year old), we observe a de-
crease for the majority of the peptide levels for infants (Fig. 4b). To
study the complement levels in more detail during early development
the child control group was divided into four separate age classes:
0–6 months, 7–12 months, 13–24 months and 2–18 years old, which
were then each compared to adult levels using ANOVA.Most of the pep-
tides show an increasing trend during aging (Fig. 4c–e) and a limited
number of these peptides had signiﬁcantly lower levels in individuals
of ≤6 months: C1QA (SLG), C1QB (FDH), C1QC (FQS) C1R (GYG), C5
(ILS, ITH, ELS), C8 (MES, IPG), C9 (VVE, LSP, TSN), C4BP (LSL, ALL),
ﬁcolin-3 (LLG), CFAB (DAQ, STG, YGL), and clusterin (ASS, IDS). The pep-
tides of C1QC, C1R, Ficolin-3, C4BPA, C4BPB, FB reach the adult levels
within one year (Fig. 4c), C5, C8A, C9 reach the adult levels after
N1 year (Fig. 4d) and C1QA, C1QB, C8B, clusterin in 2 years (Fig. 4e). Re-
markably, levels of two peptides situated in the beta chain of C5 ap-
peared to increase again in adulthood (N18 years old). Furthermore,
no gender associated effects were found for any of the peptides (Fig. 4f).
3.5. Complement levels in health and during infectious disease
The complement system acts as a cascade of chain-reactions and is
quickly activated upon contact with antibodies (classical pathway), ab-
errant carbohydrate structures (lectin pathway) or foreign substances
(alternative pathways). We investigated whether activation as a conse-
quence of infection has an inﬂuence on the circulating levels of comple-
ment proteins. The multiplex MRM assay was used to compare the
complement proﬁles between the group healthy (Fig. 5a) and infected
individuals (Fig. 5b) by means of univariate correlation matrix proﬁles
based on Pearson's correlation and hierarchical clustering. A change in
proﬁles was observed between the two groups, showing a stronger20 25
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308 E. Willems et al. / EBioMedicine 45 (2019) 303–313correlation between the peptides in the infected group as compared to
the control group, which is partly due to the slight increase in comple-
ment protein levels after infection.
On the contrary, some proteins were produced at lower levels in all
patients as compared to controls, including C1QB (FDH, GNL), C1QC
(FQS), C1R (GYG), C5 beta chain (ISL,ITH), C6 (ALN), C7 (LSG), clusterin
(ASS), which are primarily the same proteins as those produced at
lower levels during infancy (Fig. S4).
To further explore the differences between the controls and the pa-
tients with a viral or bacterial infection we performed principle compo-
nent analysis (PCA) (Fig. 6a). The PCA score plot shows a separation
between the control and patient sample clusters on the ﬁrst PCA axis,
accounting for 22% of the variation in the data. This discrimination
was not inﬂuenced by gender (Fig. 6a). Both infection groups show a
large overlap for all the principle components. The similarity between
bacterial to viral infection for all peptides is emphasized by a correlation
plot (Fig. 6b). Here, out of the 64 peptides, CRP (ESD), C4BPA (YTC) and
clusterin (ASS, IDS) show an increased or a decreased ratio for a bacte-
rial infection, respectively. By means of a t-test we determined which
single peptideswere signiﬁcantly different betweenpatientswith a bac-
terial or a viral infection. CRP (ESD) levels were higher in the bacterial
group as compared to the viral group, whereas clusterin (IDS) was sig-
niﬁcantly lower (Fig. 6c).
In order to assess if a combination of peptides can be used to dis-
criminate the groups we used random forest analysis. The top ﬁve
highest classiﬁers were CRP (ESD), clusterin (IDS, ASS), collectin11
(VFI) and C1QC (FQS) (Fig. 6d). To test if the random forest model
based on all features could enhance the predictive power of CRP for bac-
terial infection we compared the area under the curve (AUC) of the re-
ceiver operating characteristic (ROC) curve for the clinical CRP levels
(AUC = 0·9046) to the slightly higher random forest model (AUC =
0·9216) (Fig. 6e). This showed that ourMRMassay is at least equally ef-
fective in predicting bacterial versus viral outcome as compared to the
current clinical standard.3.6. Following the kinetics of circulating complement proteins during
bacterial infections
Apart from increased CRP (ESD) and reduced clusterin (ASS, IDS)
levels, no other of the 64 complement peptide levels were signiﬁcantly
altered at the time the patient samples were collected for the clinical
study. However, this is only a snapshot of the complement system at
the start of infection, as the samples were taken shortly after admission
to the hospital. In order to study the complement peptides during infec-
tion, we measured the levels of the complement peptides at multiple
timepoints:within 24 h after hospital admission (T=1), 48 h after hos-
pital admission (T= 2), and at recovery (T= 3). We focused on infec-
tions with Streptococcus pyogenes, Neisseria meningitidis serogroup B,
Streptococcus pneumoniae and Staphylococcus aureus (Full overview in
Fig. S5).
In these longitudinal samples we observed that the peptide level of
CRP (ESD) was decreased in time to basal levels for most patients
(Fig. 7a), whereas clusterin peptide (ASS, IDS) levels increased
(Fig. 7bc), which seems to be the strongest and above basal levels for
S. pyogenes and S. pneumoniae. Also MASP1 (SLP) (Fig. 7d) and factor
H (SSN) (Fig. 7e) increased 2-fold after infection with S. pyogenes as
compared to the other infections. These patients stayed relatively longer
(average 31 days) in the hospital than the other patients (average
9 days), indicating a higher severity of infection. Although we expect a
decrease to normal levels after complete recovery, we do not have any
follow up samples to conﬁrm this. Apart from these trends for
S. pyogenes, we were not able to ﬁnd other changes between the differ-
ent types of infection or allocate distinct complement proteins that alter
signiﬁcantly in time; themajority of complement proteins did not show
large ﬂuctuations over time, as shown for ﬁcolin3 (LLG) in Fig. 7f. Fur-
thermore, we did not observe a difference in patterns between infection
with Gram positive and Gramnegative bacteria. An overview of all pep-
tides is provided in Fig. S5.
4. Discussion
Multiple techniques and assays have been developed to measure
concentrations of single complement proteins. However, complement
proteins are part of a whole system acting in concert, which demands
for a sensitive measurement to determine global changes in levels in a
multiplex fashion. We used a targeted proteomics approach in which
the mass spectrometer is programmed to detect speciﬁc peptides de-
rived from the proteins of interest.
The MRM assay was technically validated based on linearity, intra-
assay variation (reproducibility), inter-assay variation (robustness)
and inter-operator variation. We found that 64 out of 86 targeted pep-
tides were suitable (CV b 20% for the above mentioned parameters) to
obtain a robust proﬁle of 32 different complement proteins, indicating
the importance of a technical validation as part of the assay develop-
ment phase. Clinically determined CRP values of the patient cohort
were used as a benchmark for the biological validation. We found that
the CRP peptide levels measured by the MRM assay strongly correlated
with the CRP levels measured by the highly standardized clinical assay.
These technical and biological validation results provided a good foun-
dation to continue with the data analysis of other complement levels
in both healthy individuals and patients with infectious disease.
To our knowledge this is the ﬁrst time that 32 complement proteins
have been studied simultaneously in healthy individuals ranging from 0
to 55 years of age. We found some conﬂicting results in the literature
concerning basal complement levels in young infants, the age that
these levels reach adult levels and their dependency on gender
[16,25]. In our study, no gender differences were observed for either
the (pediatric or adult) control group or the patient group for any of
the MRM complement peptides. Although gender-dependent differ-
ences in immune responses are known [44], it seems that this is not
reﬂected by the expression levels of complement system components.
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Fig. 5. Comparing the complement peptides in health and disease. (a) Correlationmatrix of all 64 peptides for all healthy controls. (b) Correlationmatrix of all 64 peptides for all patients.
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310 E. Willems et al. / EBioMedicine 45 (2019) 303–313When we compared the age differences in our healthy individuals,
we observed an equal distribution of complement levels among the pe-
diatric and adult group. However, when looking at infant levels speciﬁ-
cally, we did observe signiﬁcantly lower levels for approximately one
third of the peptides; partially conﬁrming earlier studies reporting
lower levels in infants for most complement proteins [16].
To explain the biological background of the differences in levels be-
tween age groups for this distinct subset of complement proteins,we in-
vestigated possible associations with speciﬁc pathways, the location of
protein production and the chromosomal locus. No speciﬁc relation
with the site of production or chromosomal locus was found. However,
there was a small trend in pathway speciﬁcity: lower infant levels were
found for peptides from proteins at the beginning of the classicalpathway (C1QA, C1QB, C1R). The majority of these peptides also de-
creased to lower levels during infection; whereas peptides that were
at adult level during infancy stay at those adult levels during infection.
Furthermore, it appeared that the majority of regulating (inhibitory)
proteins, such as C1-inhibitor, factor D, factor H, factor I, were already
at adult levels in newborns. This indicates that strict control of comple-
ment activation is important right after birth.
Moreover, from the data on the kinetics of complement proteins
measured at hospital admission during infection and after recovery
we deduce that this high rate of homeostasis of regulating proteins is
also maintained during invasive bacterial infections.
Expression of the complement proteins appears surprisingly stable
in patients challenged with bacterial or viral infections. This indicates
Fig. 7.Kinetics of complement protein levels during bacterial infectionwith eitherN.meningitidis (n=3 individuals), S. aureus (n=2), S. pneumoniae (n=3) or S. pyogenes (n=3),with
T1 (hospital admission), T2 (48h post-admission) and T3 (recovery), compared to average child control values (± std.dev. indicated by gray area), depicted for the peptides (a) CRP (ESD),
(b) clusterin (ASS), (c) clusterin (IDS), (d)MASP1 (SLP), (e) factor H (SSN), (f) ﬁcolin3 (LLG). A heat map overview of all peptides is included in Fig. S5.
311E. Willems et al. / EBioMedicine 45 (2019) 303–313that there is no measurable consumption and suggests continuous re-
plenishment of complement proteins. Furthermore, as expression of
complement proteins is determined by constitutive rather than respon-
sive expression it is conceivable that complement regulation takes place
through both activation and post-translational modiﬁcation. An excep-
tion to this observation is an increase and decrease of CRP and clusterin
levels, respectively. CRP is currently used as clinical biomarker for bacte-
rial infection. However, the exact function of clusterin in the context of
infectious diseases is still unclear. Clusterin - or apolipoprotein J - is a
stress-induced chaperone protein, which prevents the formation of
the MAC-complex within the membrane by inhibiting C7, C8 and C9
[2]. Reduced levels of clusterin have previously been observed for sepsis
patients [45] and even complete absence duringmalaria infections [46].
Also direct interaction of clusterin and pathogens [47,48], or their pro-
duced proteins [46,49], have been reported. In those cases clusterin
prevented pathogen (protein) induced inﬂammatory responses [46],
cell damage [45] or apoptosis [49]. Additional studies are required to
further elucidate on its protective properties in infectious diseases.
Although we hypothesized that there might be pathway-speciﬁc al-
tering complement levels in bacterial and viral infections, we only iden-
tiﬁed small differences in complement levels measured in plasma from
children in this pilot study. The complement system did not seem to
have pathogen-speciﬁc activation pathways reﬂected by altered expres-
sion levels of speciﬁc complement proteins.
A ROC curve based on the random forest model, trained on the
highest discriminators, performs similarly to the current clinical assay.
The MRM assay is thus a promising method to simultaneously proﬁle
the complement system and to serve as a diagnostic tool. However,
this pilot study was conducted to demonstrate a new approach to
study the complement system in a multiplex fashion. For diagnostic
purposes the assay requires additional optimization such as the use of
highly puriﬁed internal standards for absolute quantiﬁcation and auto-
mation of the sample preparation procedure to enhance throughput
and further reduce technical variability.Especially for diagnostic purposes, absolute quantiﬁcation is re-
quired in order to compare results analyzed at different laboratories
and obtained with quantitative tests. Due to advancements in technol-
ogy and development of new applications, Jannetto et al. envision an in-
creasing trend in the implementation of mass spectrometry for clinical
applications [50]. Although several mass spectrometers are listed as
in vitro diagnostic medical devices, currently only one quantitative
LC-MS assay kit has FDA clearance [51]. A standardized approach for de-
velopment and veriﬁcation was recently published by the Clinical and
Laboratory Standards Institute (CLSI) to further enhance the implemen-
tation of this technology in clinical laboratories [51].
For instance, this MRM assay could then be a unique tool for moni-
toring other complement mediated diseases such as age-related macu-
lar degeneration (AMD), angioedema, antibody-mediated rejection, or
autoimmunediseases like: rheumatoid arthritis (RA) atypical hemolytic
uremic syndrome (aHUS), systemic lupus erythematosus (SLE) [52].
Furthermore, this MRM assay could help in quickly conﬁrming a
(suspected) complement deﬁciency, since this process now is very labo-
rious consisting of several consecutive ELISAs to ﬁnd the affected pro-
tein(s).
The requirement of little amounts of sample and the reducing condi-
tions of the sample pretreatment prior to this mass spectrometric assay
facilitate measurement of various sample types. With this multiplex
assay we are currently able to measure complement peptides in
serum, plasma, CSF, throat samples, nose swabs, urine and cell culture
medium (data not shown). This creates opportunities to use this multi-
plex assay to investigate complement levels in other, less invasive, parts
of the body and as readout of both in vitro experiments as well as (aug-
mentation of) clinical diagnostics.
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